Stoke Therapeutics, Inc. (STOK) Market Cap & Valuation Ratios
Stoke Therapeutics, Inc. (STOK) has a market cap of $1.6B and a price-to-sales ratio of 58.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STOKStoke Therapeutics, Inc.Follow STOK — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| STOK | 1.6 | — | 48.0 | — | -11.2% | -86% | — | -95% |
| MAZE | 1.7 | — | — | — | -6.2% | — | — | -50% |
| URGN | 1.7 | — | 9.4 | — | -9.4% | +100% | -35% | — |
| KLRA | 1.7 | — | — | — | — | — | — | — |
| NUVB | 1.6 | — | 7.0 | — | -8.0% | +1084% | -81% | -65% |
| NVAX | 1.6 | — | 2.8 | — | -2.7% | -62% | -57% | — |
| IMCR | 1.6 | — | 2.6 | — | -2.6% | +21% | -5% | -7% |
| ABSI | 1.6 | — | 880.5 | — | -6.9% | -62% | — | -92% |
| TRAX | 1.6 | — | — | — | — | — | — | — |
| NTLA | 1.6 | — | 19.0 | — | — | +13% | — | -68% |
| RARE | 1.5 | — | 1.7 | — | — | +18% | -74% | — |
| Median of these 10 | — | 7.0 | — | -6.6% | +18% | -57% | -65% |
; EV/Sales 48.0 vs. 7.0.
Growth vs. price
each dot a company · hover or tap for valuesStoke Therapeutics, Inc. — questions
- What is Stoke Therapeutics, Inc.'s market cap?
- $1.6B.
- What is Stoke Therapeutics, Inc.'s price-to-sales ratio?
- 58.6.
Every figure on this page comes from Stoke Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.